0
0
4/6/23 at 4:00pm
Organization
Newswise
Author
Johns Hopkins Medicine
37 words
0
Comments
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer through
6 similar articles
You are the first to view
https://www.newswise.com/articles/novel-immunotherapy-agent-safe-shows-promise-against-high-risk-prostate-cancers
Create an account
or login to join the discussion